Related Experiment Videos
Overview of anticoagulant drugs for the future
Stephan Moll1, Harold R Roberts
1Department of Medicine, Division of Hematology-Oncology, Center for Thrombosis and Hemostasis, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7035, USA.
Abstract:
More efficacious, safer, and easier to use anticoagulants are under development. Multiple agents have been shown to be effective in ex vivo or animal thrombosis models and several have progressed to clinical studies. Investigators have not yet determined if pharmaceuticals that inhibit coagulation factor activity earlier in the cascade (for example, inhibitors of tissue factor/factor VIIa, factor IXa, or Xa) are superior to those that block the cascade at a later point. Orally bioavailable drugs for the long-term treatment of thrombotic disorders, particularly those that do not require monitoring, are needed and are under development. Local delivery of anticoagulants or genes modulating anticoagulant control at sites of increased thrombogenicity, such as in diseased arteries, is a promising treatment modality that may decrease systemic bleeding problems. Much about the initiating pathophysiologic events leading to venous thrombotic disease needs to be elucidated before such local therapy can be tested in the venous vasculature. While awaiting better anticoagulants to become routinely available, we need to improve patient management with existing drugs by instituting anticoagulation clinics, promoting patient self-monitoring, and improving efforts to educate patients and health care providers about the use of anticoagulant drugs.
Insights
New anticoagulants are being developed for safer and more effective thrombosis treatment. Improved patient management with existing drugs and local delivery methods are also key areas of research.
Area of Science:
- Pharmacology
- Hematology
- Biomedical Engineering
Background:
- Development of novel anticoagulants aims for improved efficacy, safety, and ease of use compared to current therapies.
- Existing anticoagulants show promise in preclinical models, with several advancing to clinical trials for thrombotic disorders.
Purpose of the Study:
- To evaluate the potential superiority of early-acting coagulation cascade inhibitors (e.g., tissue factor/factor VIIa, factor IXa, factor Xa inhibitors) over later-acting agents.
- To highlight the need for orally bioavailable, non-monitoring anticoagulants for long-term thrombotic disorder management.
- To explore local anticoagulant delivery as a strategy to minimize systemic bleeding risks.
Main Methods:
- Review of existing literature on anticoagulant development and clinical studies.
- Analysis of preclinical data from ex vivo and animal thrombosis models.
- Discussion of potential therapeutic strategies including early cascade inhibition and local delivery.
Main Results:
- Multiple anticoagulant agents are under investigation, with varying targets within the coagulation cascade.
- Orally bioavailable drugs that do not require monitoring are a significant unmet need.
- Local delivery of anticoagulants presents a promising approach for targeted therapy.
Conclusions:
- Further research is needed to determine the optimal target within the coagulation cascade for novel anticoagulants.
- Improving patient management with existing anticoagulants through education and monitoring is crucial.
- Local delivery strategies hold potential but require further understanding of venous thrombotic disease pathophysiology.